Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKTNASDAQ:APDNNYSE:DYNASDAQ:GDYNNASDAQ:IOVANASDAQ:NVAX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKTAlkami Technology$30.63+4.8%$29.04$21.70▼$42.29$3.15B0.59911,372 shs619,664 shsAPDNApplied DNA Sciences$4.70-4.9%$7.83$4.37▼$2,655.00$2.07M0.0747,187 shs57,282 shsDYDycom Industries$250.36+1.3%$217.99$131.37▼$251.73$7.24B1.32422,042 shs209,370 shsGDYNGrid Dynamics$12.36+3.3%$12.80$10.15▼$25.50$1.05B1.04670,669 shs500,959 shsIOVAIovance Biotherapeutics$1.75+0.2%$2.15$1.64▼$12.51$585.71M0.858.98 million shs4.64 million shsNVAXNovavax$6.80+0.5%$6.76$5.01▼$17.81$1.10B2.696.28 million shs2.29 million shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKTAlkami Technology0.00%+3.05%+0.54%+34.08%+0.57%APDNApplied DNA Sciences0.00%-2.69%-12.48%-75.90%-98.58%DYDycom Industries0.00%+1.99%+3.06%+77.80%+47.77%GDYNGrid Dynamics0.00%+5.91%+1.73%-9.78%+17.94%IOVAIovance Biotherapeutics0.00%+3.79%-14.44%-42.11%-75.91%NVAXNovavax0.00%+6.67%-8.79%+3.90%-42.90%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALKTAlkami Technology3.591 of 5 stars4.41.00.00.03.13.30.6APDNApplied DNA Sciences0.2199 of 5 stars0.02.00.00.01.60.00.6DYDycom Industries3.7336 of 5 stars2.63.00.02.62.41.71.3GDYNGrid Dynamics2.901 of 5 stars3.62.00.00.03.92.50.0IOVAIovance Biotherapeutics4.7005 of 5 stars4.31.00.04.21.74.21.3NVAXNovavax4.4928 of 5 stars3.12.00.04.71.30.83.1Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKTAlkami Technology 2.75Moderate Buy$39.2528.16% UpsideAPDNApplied DNA Sciences 0.00N/AN/AN/ADYDycom Industries 3.13Buy$241.25-3.64% DownsideGDYNGrid Dynamics 3.20Buy$18.7551.70% UpsideIOVAIovance Biotherapeutics 2.50Moderate Buy$12.22596.82% UpsideNVAXNovavax 2.29Hold$17.00150.18% UpsideCurrent Analyst Ratings BreakdownLatest IOVA, APDN, ALKT, GDYN, NVAX, and DY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2025ALKTAlkami TechnologyJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$45.00 ➝ $40.006/17/2025NVAXNovavaxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageSell$6.005/27/2025DYDycom IndustriesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$215.00 ➝ $250.005/23/2025DYDycom IndustriesDA DavidsonSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$220.00 ➝ $265.005/23/2025DYDycom IndustriesB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$200.00 ➝ $265.005/22/2025DYDycom IndustriesRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetStrong-Buy ➝ Strong-Buy$215.00 ➝ $255.005/22/2025DYDycom IndustriesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $250.005/22/2025DYDycom IndustriesUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$234.00 ➝ $258.005/19/2025NVAXNovavaxB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/19/2025DYDycom IndustriesWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$200.00 ➝ $215.005/16/2025IOVAIovance BiotherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral$17.00 ➝ $2.00(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKTAlkami Technology$333.85M9.45N/AN/A$3.55 per share8.63APDNApplied DNA Sciences$3.43M0.60N/AN/A$215.25 per share0.02DYDycom Industries$4.70B1.54$15.06 per share16.62$42.76 per share5.85GDYNGrid Dynamics$350.57M2.98$0.35 per share35.76$6.19 per share2.00IOVAIovance Biotherapeutics$164.07M3.57N/AN/A$2.33 per share0.75NVAXNovavax$682.16M1.61N/AN/A($3.89) per share-1.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKTAlkami Technology-$40.83M-$0.38N/AN/AN/A-10.47%-7.06%-4.56%7/30/2025 (Estimated)APDNApplied DNA Sciences-$6.99M-$537.48N/A∞N/A-194.14%-66.95%-50.34%8/6/2025 (Estimated)DYDycom Industries$233.41M$7.8931.7331.021.434.81%20.04%8.22%8/20/2025 (Estimated)GDYNGrid Dynamics$4.04M$0.12103.01∞N/A2.94%1.37%1.19%7/31/2025 (Estimated)IOVAIovance Biotherapeutics-$372.18M-$1.24N/AN/AN/A-176.49%-49.71%-39.18%8/6/2025 (Estimated)NVAXNovavax-$187.50M$2.652.5684.940.0638.14%-115.51%29.99%8/14/2025 (Estimated)Latest IOVA, APDN, ALKT, GDYN, NVAX, and DY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/31/2025Q2 2025GDYNGrid Dynamics$0.09N/AN/AN/A$100.45 millionN/A7/30/2025Q2 2025ALKTAlkami Technology$0.08N/AN/AN/A$109.93 millionN/A5/21/2025Q1 2026DYDycom Industries$1.62$2.09+$0.47$2.09$1.19 billion$1.26 billion5/15/2025Q2 2025APDNApplied DNA Sciences-$45.00-$230.25-$185.25-$15.35$1.19 million$0.98 million5/8/2025Q1 2025IOVAIovance Biotherapeutics-$0.25-$0.36-$0.11-$0.36$83.40 million$49.32 million5/8/2025Q1 2025NVAXNovavax$0.71$2.93+$2.22$2.93$204.08 million$666.66 million5/1/2025Q1 2025GDYNGrid Dynamics$0.09$0.11+$0.02$0.03$98.19 million$100.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKTAlkami TechnologyN/AN/AN/AN/AN/AAPDNApplied DNA SciencesN/AN/AN/AN/AN/ADYDycom IndustriesN/AN/AN/AN/AN/AGDYNGrid DynamicsN/AN/AN/AN/AN/AIOVAIovance BiotherapeuticsN/AN/AN/AN/AN/ANVAXNovavaxN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKTAlkami Technology1.232.752.75APDNApplied DNA SciencesN/A4.454.27DYDycom Industries0.802.892.68GDYNGrid DynamicsN/A7.257.25IOVAIovance BiotherapeuticsN/A4.183.64NVAXNovavaxN/A2.062.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKTAlkami Technology54.97%APDNApplied DNA Sciences22.22%DYDycom Industries98.33%GDYNGrid Dynamics71.18%IOVAIovance Biotherapeutics77.03%NVAXNovavax53.04%Insider OwnershipCompanyInsider OwnershipALKTAlkami Technology18.10%APDNApplied DNA Sciences0.17%DYDycom Industries3.72%GDYNGrid Dynamics7.20%IOVAIovance Biotherapeutics10.30%NVAXNovavax1.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKTAlkami Technology850103.02 million84.37 millionOptionableAPDNApplied DNA Sciences70440,000434,000OptionableDYDycom Industries15,62328.92 million27.85 millionOptionableGDYNGrid Dynamics4,73084.55 million78.46 millionOptionableIOVAIovance Biotherapeutics500333.93 million299.54 millionOptionableNVAXNovavax1,990161.97 million160.35 millionOptionableIOVA, APDN, ALKT, GDYN, NVAX, and DY HeadlinesRecent News About These CompaniesNovavax Inc. Research & Ratings | NVAX - Barron'sJuly 6 at 9:53 PM | barrons.comNovavax, Inc. (NVAX) Latest Stock News & Headlines - Yahoo FinanceJuly 3, 2025 | finance.yahoo.comRFK Jr. Influence Evident As Vaccine Chief Overrules Scientists, Limits COVID-19 Vaccine ApprovalJuly 3, 2025 | benzinga.comRFK Jr.‘s top FDA vaccine official restricts 2 COVID vaccine approvals against advice of agency scientistsJuly 3, 2025 | fortune.comModerna’s Shares Gain in Premarket as New Flu Shot Shows Promising ResultsJuly 1, 2025 | tokenist.comTIs Most-Watched Stock Novavax, Inc. (NVAX) Worth Betting on Now?July 1, 2025 | zacks.comNovavax (NVAX) Stock Slides as Market Rises: Facts to Know Before You TradeJune 27, 2025 | zacks.comVaccines and antibodies up for debate at CDC advisory panel meetingJune 26, 2025 | reuters.comNovavax Approval Process a Potential ‘Harbinger’ of Threat to FDA Integrity: Former RegulatorsJune 26, 2025 | biospace.comBNovavax, Inc. (NVAX) latest stock news and headlines - Yahoo FinanceJune 25, 2025 | uk.finance.yahoo.comWhy Investors Need to Take Advantage of These 2 Medical Stocks NowJune 24, 2025 | zacks.comNovavax Shareholders Approve Key Proposals at Annual MeetingJune 24, 2025 | tipranks.comNotable healthcare headlines for the week: Eli Lilly, Novavax and Sarepta Therapeutics in focusJune 22, 2025 | msn.comNovavax Faces Challenges Amid Stock DeclineJune 21, 2025 | tipranks.comNovavax (NVAX) Ascends While Market Falls: Some Facts to NoteJune 20, 2025 | zacks.comNovavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should KnowJune 19, 2025 | zacks.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | seekingalpha.comNovavax slips as Citi launches with Sell rating on pipeline concernsJune 17, 2025 | msn.comNovavax (NASDAQ:NVAX) Shares Gap Down - Should You Sell?June 17, 2025 | marketbeat.comNovavax (NASDAQ:NVAX) Earns Sell Rating from Analysts at CitigroupJune 17, 2025 | marketbeat.comNovavax, Inc. (NASDAQ:NVAX) Given Average Recommendation of "Moderate Buy" by BrokeragesJune 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack Mode3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingBy Chris Markoch | June 29, 2025View 3 Biotech Stocks to Watch: Iovance, Neurocrine & VikingIOVA, APDN, ALKT, GDYN, NVAX, and DY Company DescriptionsAlkami Technology NASDAQ:ALKT$30.62 +1.40 (+4.77%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$30.62 -0.01 (-0.03%) As of 07/3/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkami Technology, Inc. offers cloud-based digital banking solutions in the United States. The company's Alkami Platform allows financial institutions to onboard and engage new users, accelerate revenues, and enhance operational efficiency, with the support of a proprietary, cloud-based, and multi-tenant architecture. It serves community, regional, super-regional credit unions, and banks. The company was founded in 2009 and is headquartered in Plano, Texas.Applied DNA Sciences NASDAQ:APDN$4.70 -0.24 (-4.86%) Closing price 07/3/2025 03:20 PM EasternExtended Trading$4.70 0.00 (-0.11%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Applied DNA Sciences, Inc., a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services. The Therapeutic DNA Production Services segment develops and commercializes the LinearDNA platform, which enables a cell-free manufacture of high-fidelity synthetic DNA sequences for use in nucleic acid-based therapeutics. The MDx Testing Services segment provides clinical molecular diagnostics (MDx) testing and clinical laboratory testing services; COVID-19 testing services, including test scheduling, sample collection, and automated results reporting for higher education institutions, private clients, and businesses under the safeCircle trademark; polymerase chain reaction (PCR) for production and detection of DNA and RNA; and MDx test kits and related supplies, as well as Isotopic analysis testing services. The DNA Tagging and Security Products and Services segment offers SigNature Molecular Tags, which provides a methodology to authenticate goods within large and complex supply chains for materials, such as cotton, nutraceuticals, and other products; SigNify portable DNA readers and SigNify consumable reagent test kits; and fiberTyping, which uses PCR-based DNA detection to detect a product's naturally occurring DNA sequences for the purposes of product provenance authentication and supply chain security. The company was formerly known as Datalink Systems, Inc. and changed its name to Applied DNA Sciences, Inc. in 2002. Applied DNA Sciences, Inc. was founded in 1983 and is headquartered in Stony Brook, New York.Dycom Industries NYSE:DY$250.36 +3.17 (+1.28%) Closing price 07/3/2025 03:34 PM EasternExtended Trading$250.36 0.00 (0.00%) As of 04:38 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dycom Industries, Inc. provides specialty contracting services to the telecommunications infrastructure and utility industries in the United States. The company offers engineering services to telecommunications providers, including the planning and design of aerial, underground, and buried fiber optic, copper, and coaxial cable systems; wireless networks in connection with the deployment of macro cell and new small cell sites; and program and project management and inspection personnel. It also provides construction, maintenance, and installation services for telephone companies and cable multiple system operators, such as placement and splicing of copper, fiber, and coaxial cables; tower construction, lines and antenna installation, foundation and equipment pad construction, and small cell site placement for wireless carriers, as well as equipment installation and material fabrication, and site testing services; underground facility locating services comprising locating telephone, cable television, power, water, sewer, and gas lines; installation and maintenance of customer premise equipment, including digital video recorders, set top boxes, and modems for cable system operators; and construction and maintenance services for electric and gas utilities, and other customers. Dycom Industries, Inc. was incorporated in 1969 and is headquartered in Palm Beach Gardens, Florida.Grid Dynamics NASDAQ:GDYN$12.36 +0.40 (+3.34%) Closing price 07/3/2025 02:52 PM EasternExtended Trading$12.36 0.00 (0.00%) As of 07/3/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Grid Dynamics Holdings, Inc., together with its subsidiaries, provides technology consulting, platform and product engineering, and analytics services in North America, Europe, and internationally. It offers cloud platform and product engineering services, such as architecting, designing, and building scalable and secure cloud-based platforms and business applications; and AI/machine learning and data platform engineering services that build platforms to facilitate batch and streaming data ingestion, quality governance, orchestration, semantic modeling, observability, and analysis at scale. The company provides digital engagement services, including digital ecosystem design and implementation; and supply chain, Internet of Thing, and advanced manufacturing, which focuses on transforming traditional operations into smart and connected ecosystems. It serves customers that operate in the tech, media, telecommunications, retail, consumer packaged goods, manufacturing, and finance industries. The company was formerly known as ChaSerg Technology Acquisition Corp. and changed its name to Grid Dynamics Holdings, Inc. Grid Dynamics Holdings, Inc. was founded in 2006 and is headquartered in San Ramon, California.Iovance Biotherapeutics NASDAQ:IOVA$1.75 +0.00 (+0.23%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$1.74 -0.01 (-0.51%) As of 05:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.Novavax NASDAQ:NVAX$6.80 +0.04 (+0.52%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$6.79 0.00 (-0.07%) As of 05:05 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/30 - 07/04 The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Correction Equals Opportunity in Domino’s Pizza Stock Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
